{"id":"maxidex","rwe":[],"tags":[],"trials":[],"_chembl":{"chemblId":"CHEMBL1201302","moleculeType":"Small molecule","molecularWeight":"472.45"},"aliases":["Dexamethasone 0.1% eyedrop"],"patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$16.5916/ML","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$5,973","description":"MAXIDEX 0.1% EYE DROPS","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Maxidex","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:56:34.901078+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:56:39.993677+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Maxidex","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:56:40.306382+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201302/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:56:41.024823+00:00"}},"offLabel":[],"timeline":[],"_dailymed":{"setId":"35e47fcd-e020-43e5-8322-41f8060d220d","title":"MAXIDEX (DEXAMETHASONE) FOR SUSPENSION [HARROW EYE, LLC]"},"ecosystem":[],"_scrapedAt":"2026-03-27T23:53:58.143Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:56:42.708743+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia","enrollment":153},{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome","enrollment":6720},{"nctId":"NCT03798678","phase":"PHASE1","title":"CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-08","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":36},{"nctId":"NCT06169215","phase":"PHASE2","title":"Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-07-23","conditions":"Multiple Myeloma","enrollment":70},{"nctId":"NCT07463807","phase":"PHASE1, PHASE2","title":"Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-26","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":162},{"nctId":"NCT07494136","phase":"PHASE4","title":"Dose Dependent Steroid Injections","status":"NOT_YET_RECRUITING","sponsor":"University of Miami","startDate":"2026-05","conditions":"Lumbar Radiculopathy, Sciatica, Back Pain With Radiation","enrollment":150},{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":97},{"nctId":"NCT06948084","phase":"PHASE2","title":"Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-29","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":80},{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":348},{"nctId":"NCT04847453","phase":"PHASE1","title":"Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-03","conditions":"Recurrent AL Amyloidosis, Refractory AL Amyloidosis","enrollment":24},{"nctId":"NCT07444710","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-20","conditions":"Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma, Ann Arbor Stage IV Mantle Cell Lymphoma","enrollment":16},{"nctId":"NCT00644228","phase":"PHASE3","title":"Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-07-28","conditions":"DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma","enrollment":525},{"nctId":"NCT04835129","phase":"PHASE2","title":"Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2022-01-10","conditions":"Multiple Myeloma","enrollment":28},{"nctId":"NCT05519085","phase":"PHASE3","title":"A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)","status":"RECRUITING","sponsor":"Celgene","startDate":"2022-09-20","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":810},{"nctId":"NCT06235567","phase":"PHASE1, PHASE2","title":"Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking","status":"ENROLLING_BY_INVITATION","sponsor":"Maanasa Indaram, MD","startDate":"2025-04-11","conditions":"Keratoconus","enrollment":20},{"nctId":"NCT01297764","phase":"PHASE1, PHASE2","title":"A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2011-04","conditions":"Multiple Myeloma","enrollment":17},{"nctId":"NCT02773030","phase":"PHASE1, PHASE2","title":"A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2016-10-14","conditions":"Multiple Myeloma","enrollment":466},{"nctId":"NCT06136598","phase":"PHASE1","title":"A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-01-30","conditions":"Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer","enrollment":14},{"nctId":"NCT07480863","phase":"PHASE2","title":"Treatment of BTKi+Hi-CVP Regimen for Previously Untreated MZL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-10-01","conditions":"Marginal Zone Lymphoma(MZL)","enrollment":65},{"nctId":"NCT02491632","phase":"PHASE2, PHASE3","title":"Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-08-13","conditions":"Advanced Malignant Neoplasm, Fatigue, Metastatic Malignant Neoplasm","enrollment":90},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":"Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT05272826","phase":"PHASE2","title":"Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients","status":"RECRUITING","sponsor":"Canadian Myeloma Research Group","startDate":"2024-12-12","conditions":"Multiple Myeloma","enrollment":75},{"nctId":"NCT06207123","phase":"PHASE1, PHASE2","title":"A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2024-09-13","conditions":"Acute Leukemia, Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":15},{"nctId":"NCT06918431","phase":"PHASE2","title":"Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-10-10","conditions":"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic Lymphoma","enrollment":53},{"nctId":"NCT05552976","phase":"PHASE3","title":"A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2023-01-10","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":525},{"nctId":"NCT05690984","phase":"PHASE2","title":"Elimination of Minimal Residual Disease After Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2023-06-26","conditions":"Multiple Myeloma","enrollment":30},{"nctId":"NCT04883242","phase":"PHASE2","title":"Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2021-07-29","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":30},{"nctId":"NCT06348108","phase":"PHASE1","title":"Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Alfred Chung, MD","startDate":"2025-07-28","conditions":"Multiple Myeloma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma","enrollment":32},{"nctId":"NCT03661645","phase":"PHASE4","title":"Post-operative Methylprednisolone Taper Course for Orthopedic Surgery","status":"ENROLLING_BY_INVITATION","sponsor":"Emory University","startDate":"2018-09-07","conditions":"Orthopedic Surgeries","enrollment":500},{"nctId":"NCT05292664","phase":"PHASE1","title":"Venetoclax Basket Trial for High Risk Hematologic Malignancies","status":"RECRUITING","sponsor":"Andrew E. Place, MD","startDate":"2023-03-29","conditions":"Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated","enrollment":30},{"nctId":"NCT04151667","phase":"PHASE2","title":"Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-11-22","conditions":"Multiple Myeloma","enrollment":33},{"nctId":"NCT01572480","phase":"PHASE2","title":"Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-05-29","conditions":"Multiple Myeloma","enrollment":55},{"nctId":"NCT03959085","phase":"PHASE3","title":"Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-10-31","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia","enrollment":5951},{"nctId":"NCT06979596","phase":"PHASE2","title":"A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-08-11","conditions":"Malignant Neoplasm","enrollment":250},{"nctId":"NCT06104449","phase":"PHASE1","title":"A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-11-14","conditions":"Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer","enrollment":6},{"nctId":"NCT05730036","phase":"PHASE3","title":"A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-09-18","conditions":"Relapsed Refractory Multiple Myeloma (RRMM)","enrollment":410},{"nctId":"NCT06203912","phase":"PHASE1","title":"Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Elvira Umyarova","startDate":"2024-03-05","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":3},{"nctId":"NCT06930690","phase":"PHASE1, PHASE2","title":"Dexamethasone for Ureteral STent Symptoms (DUSTS)","status":"NOT_YET_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2026-04","conditions":"Ureteral Stent-Related Symptom","enrollment":70},{"nctId":"NCT04094961","phase":"PHASE1, PHASE2","title":"Ixazomib + Pomalidomide + Dexamethasone In MM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Omar Nadeem, MD","startDate":"2019-09-18","conditions":"Multiple Myeloma, Multiple Myeloma in Relapse","enrollment":52},{"nctId":"NCT05023369","phase":"PHASE4","title":"This is a Study to Verify if Periarticular Hip Injection of Corticosteroid After Hip Replacement Reduce the Pain and the Hospitalisation Time","status":"RECRUITING","sponsor":"Ente Ospedaliero Cantonale, Bellinzona","startDate":"2021-12-10","conditions":"Femoral Neck Fractures","enrollment":110},{"nctId":"NCT04216524","phase":"PHASE2","title":"Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-05-29","conditions":"Blastic Plasmacytoid Dendritic Cell Neoplasm","enrollment":40},{"nctId":"NCT06289673","phase":"PHASE4","title":"Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-12-26","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia","enrollment":850},{"nctId":"NCT03937635","phase":"PHASE3","title":"Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-09-16","conditions":"Smoldering Plasma Cell Myeloma","enrollment":288},{"nctId":"NCT04566328","phase":"PHASE3","title":"Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-02-24","conditions":"Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma","enrollment":1450},{"nctId":"NCT05257941","phase":"PHASE1, PHASE2","title":"ESP Block VS Intrathecal Opioid After Laparoscopic Colorectal Surgery","status":"TERMINATED","sponsor":"Indiana University","startDate":"2022-01-27","conditions":"Surgery","enrollment":116},{"nctId":"NCT04977427","phase":"PHASE4","title":"Dextenza vs Prednisolone Acetate After Cataract Surgery for Patients With Diabetes","status":"WITHDRAWN","sponsor":"Baylor Research Institute","startDate":"2021-08-31","conditions":"Cataract Diabetic, Macula Edema","enrollment":""},{"nctId":"NCT06664853","phase":"PHASE3","title":"Open-Label Extension of EryDex Study IEDAT-04-2022","status":"TERMINATED","sponsor":"Quince Therapeutics S.p.A.","startDate":"2024-12-11","conditions":"Ataxia Telangiectasia","enrollment":101},{"nctId":"NCT03283917","phase":"PHASE1","title":"Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-02-07","conditions":"Newly Diagnosed Primary Amyloidosis, Recurrent Primary Amyloidosis, Refractory Primary Amyloidosis","enrollment":21},{"nctId":"NCT06390319","phase":"PHASE2","title":"Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-12-27","conditions":"T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, Mixed Phenotype Acute Leukemia","enrollment":100},{"nctId":"NCT04764942","phase":"PHASE1, PHASE2","title":"Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2021-05-06","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":39},{"nctId":"NCT07428369","phase":"PHASE2, PHASE3","title":"A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)","status":"NOT_YET_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-06-05","conditions":"Multiple Myeloma (MM)","enrollment":1570},{"nctId":"NCT03007147","phase":"PHASE3","title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-08-08","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia","enrollment":475},{"nctId":"NCT05530421","phase":"PHASE2","title":"Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"University of Miami","startDate":"2023-03-26","conditions":"Relapsed and Refractory Multiple Myeloma","enrollment":33},{"nctId":"NCT05972135","phase":"PHASE2","title":"Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma","status":"RECRUITING","sponsor":"SCRI Development Innovations, LLC","startDate":"2023-10-23","conditions":"Multiple Myeloma","enrollment":100},{"nctId":"NCT05626478","phase":"PHASE4","title":"Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery","status":"COMPLETED","sponsor":"Nicole Fram M.D.","startDate":"2023-06-01","conditions":"Corneal Edema, Corneal Defect, Anterior Chamber Inflammation","enrollment":50},{"nctId":"NCT07082270","phase":"PHASE1","title":"Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-04-01","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":21},{"nctId":"NCT02339740","phase":"PHASE3","title":"Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2015-07-21","conditions":"Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA","enrollment":158},{"nctId":"NCT03909412","phase":"PHASE1","title":"Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma","status":"RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2019-10-08","conditions":"Multiple Myeloma","enrollment":18},{"nctId":"NCT04754945","phase":"PHASE1","title":"Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2021-04-28","conditions":"AL Amyloidosis","enrollment":11},{"nctId":"NCT03136146","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-08-09","conditions":"Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia","enrollment":42},{"nctId":"NCT04432597","phase":"PHASE1, PHASE2","title":"HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-08-11","conditions":"HPV Positive Cancer, Vulvar, Vaginal, Penile, Rectal Cancer, Anal Cancer","enrollment":39},{"nctId":"NCT05978622","phase":"","title":"Observational Study of Adult Participants With Diabetic Macular Edema and Suboptimal Response to Anti-Vascular Endothelial Growth Factor Treated With Dexamethasone Intravitreal Implant","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2023-10-30","conditions":"Diabetic Macular Edema","enrollment":236},{"nctId":"NCT07099222","phase":"PHASE1, PHASE2","title":"Efficacy of Non-weight Based, Low Dose Dex-Dex Adjuncts in Prolonging Peripheral Nerve Blocks","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arizona","startDate":"2024-10-10","conditions":"Postoperative Pain, Nausea and Vomiting, Postoperative, Dizziness","enrollment":100},{"nctId":"NCT06533748","phase":"PHASE2","title":"Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2025-01-23","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":128},{"nctId":"NCT03710772","phase":"PHASE2","title":"Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-05-01","conditions":"Mantle Cell Lymphoma","enrollment":51},{"nctId":"NCT06132685","phase":"PHASE2","title":"Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-01-09","conditions":"Low Grade Glioma, Malignant Brain Glioma, Malignant Brain Neoplasm","enrollment":200},{"nctId":"NCT04661137","phase":"PHASE2","title":"A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma","status":"SUSPENDED","sponsor":"Hackensack Meridian Health","startDate":"2021-03-16","conditions":"Multiple Myeloma","enrollment":96},{"nctId":"NCT05488847","phase":"PHASE4","title":"Opioid-Free Pain Protocol After Shoulder Arthroplasty","status":"ACTIVE_NOT_RECRUITING","sponsor":"Henry Ford Health System","startDate":"2022-06-25","conditions":"Shoulder Arthropathy, Shoulder Pain","enrollment":83},{"nctId":"NCT04371445","phase":"PHASE4","title":"Dextenza in the Post-op Management of Vitreoretinal Surgeries","status":"RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2020-06-01","conditions":"Vitreoretinal Surgery, Ocular Inflammation, Post-operative Pain","enrollment":30},{"nctId":"NCT07101445","phase":"PHASE4","title":"Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-09-24","conditions":"Multiple Myeloma","enrollment":94},{"nctId":"NCT03031730","phase":"PHASE1","title":"Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-06-14","conditions":"Plasmacytoma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":35},{"nctId":"NCT07208799","phase":"PHASE2","title":"Comparison of Submucosal Dexamethasone and Methylprednisolone in Postoperative Sequelae of Parasymphsis Fractures","status":"RECRUITING","sponsor":"Nishtar Medical University","startDate":"2026-01-03","conditions":"Mandible Fracture, Edema Face, Pain Management","enrollment":72},{"nctId":"NCT07395232","phase":"PHASE3","title":"An Efficacy and Safety Study of DFL24498 in the Treatment of AKC","status":"RECRUITING","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2025-12-01","conditions":"Atopic Keratoconjunctivitis","enrollment":138},{"nctId":"NCT04303065","phase":"PHASE3","title":"Trial of Dexamethasone for Traumatic Brain Injured Patients With Brain Contusions and Pericontusional Edema","status":"TERMINATED","sponsor":"Jon Pérez Bárcena","startDate":"2020-07-24","conditions":"Traumatic Brain Injury, Cerebral Edema, Head Injury Trauma","enrollment":600},{"nctId":"NCT06230224","phase":"PHASE3","title":"A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-02-15","conditions":"B-Cell Non-Hodgkin Lymphoma (B-NHL)","enrollment":216},{"nctId":"NCT00572169","phase":"PHASE3","title":"UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2006-11","conditions":"Multiple Myeloma","enrollment":177},{"nctId":"NCT07388069","phase":"PHASE1, PHASE2","title":"Study of TN-001 Topical Eyedrops for Keratoconus","status":"ENROLLING_BY_INVITATION","sponsor":"TheiaNova Ltd.","startDate":"2025-12-23","conditions":"Keratoconus","enrollment":20},{"nctId":"NCT05497804","phase":"PHASE2","title":"Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2022-09-22","conditions":"ISS Stage III Plasma Cell Myeloma, Multiple Myeloma","enrollment":17},{"nctId":"NCT06988488","phase":"PHASE1, PHASE2","title":"A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Celgene","startDate":"2025-10-07","conditions":"Multiple Myeloma","enrollment":62},{"nctId":"NCT04414475","phase":"PHASE2","title":"A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.","status":"RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2020-07-01","conditions":"Multiple Myeloma, Refractory","enrollment":127},{"nctId":"NCT05981209","phase":"PHASE1","title":"Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies","status":"RECRUITING","sponsor":"Abdullah Khan","startDate":"2023-12-21","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":27},{"nctId":"NCT07378215","phase":"PHASE4","title":"The Effect of Corticosteroids on Quality of Life Following Total Hip Arthroplasty: HIPSTER Study","status":"NOT_YET_RECRUITING","sponsor":"Ziekenhuis Oost-Limburg","startDate":"2026-02","conditions":"Postoperative Quality of Recovery, Health-Related Quality-of-Life, Quality of Life","enrollment":224},{"nctId":"NCT04430894","phase":"PHASE2","title":"KRDI in Transplant-Eligible MM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-07-10","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT05016947","phase":"PHASE1","title":"Venetoclax Plus Inotuzumab for B-ALL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-09-24","conditions":"B-cell Acute Lymphoblastic Leukemia, B-Cell Lymphoma, ALL","enrollment":23},{"nctId":"NCT04681105","phase":"PHASE1","title":"Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2020-11-18","conditions":"Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm","enrollment":13},{"nctId":"NCT07216820","phase":"NA","title":"Interscalene vs Phrenic-sparing Blocks in Obesity and Effect of Maximum Inspiratory Pressure","status":"RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2026-01-21","conditions":"Shoulder Surgery, Obesity","enrollment":68},{"nctId":"NCT04240054","phase":"PHASE2","title":"Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2021-11-02","conditions":"Multiple Myeloma","enrollment":41},{"nctId":"NCT06213649","phase":"PHASE3","title":"Parasitic Ulcer Treatment Trial","status":"RECRUITING","sponsor":"Jeremy Keenan, MD, MPH","startDate":"2024-07-01","conditions":"Acanthamoeba Keratitis","enrollment":232},{"nctId":"NCT05720949","phase":"PHASE4","title":"Genicular Nerve Blocks for Anterior Cruciate Ligament Knee Surgery","status":"COMPLETED","sponsor":"Hospital for Special Surgery, New York","startDate":"2023-01-12","conditions":"ACL, Anterior Cruciate Ligament Injuries","enrollment":192},{"nctId":"NCT06616584","phase":"PHASE2, PHASE3","title":"Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2025-05-22","conditions":"Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":378},{"nctId":"NCT03020030","phase":"PHASE3","title":"Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-03-03","conditions":"Acute Lymphoblastic Leukemia, Pediatric","enrollment":560},{"nctId":"NCT02718833","phase":"PHASE2","title":"A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2016-06-21","conditions":"Multiple Myeloma","enrollment":52},{"nctId":"NCT01208662","phase":"PHASE3","title":"Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65","status":"ACTIVE_NOT_RECRUITING","sponsor":"Paul Richardson, MD","startDate":"2010-09","conditions":"Multiple Myeloma","enrollment":729},{"nctId":"NCT07345819","phase":"NA","title":"Dexamethasone vs. Placebo in Children and Youth Hospitalized for Orbital Cellulitis","status":"NOT_YET_RECRUITING","sponsor":"The Hospital for Sick Children","startDate":"2026-04-01","conditions":"Orbital Cellulitis","enrollment":30},{"nctId":"NCT02813135","phase":"PHASE1, PHASE2","title":"European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2016-08-03","conditions":"Pediatric Cancer","enrollment":472},{"nctId":"NCT07343128","phase":"PHASE2, PHASE3","title":"Ultrasound-Guided Stellate Ganglion Block in Fibromyalgia","status":"COMPLETED","sponsor":"Sanliurfa Education and Research Hospital","startDate":"2025-06-01","conditions":"Fibromyalgia","enrollment":68},{"nctId":"NCT01562405","phase":"PHASE1","title":"Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2012-05","conditions":"Multiple Myeloma","enrollment":33},{"nctId":"NCT07341867","phase":"PHASE1","title":"Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype","status":"NOT_YET_RECRUITING","sponsor":"Andrew Hantel, MD","startDate":"2026-06","conditions":"Multiple Myeloma, Triple Negative Breast Cancer, Duffy Blood Group, Chemokine Receptor Gene Mutation","enrollment":90},{"nctId":"NCT02441686","phase":"PHASE2","title":"Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2015-12","conditions":"Multiple Myeloma","enrollment":46},{"nctId":"NCT06193200","phase":"PHASE3","title":"Evaluate the Neurological Effects of EryDex on Subjects With A-T","status":"COMPLETED","sponsor":"Quince Therapeutics S.p.A.","startDate":"2024-06-24","conditions":"Ataxia Telangiectasia","enrollment":105}],"_emaApprovals":[],"_faersSignals":[{"count":113,"reaction":"EYE PAIN"},{"count":97,"reaction":"VISUAL ACUITY REDUCED"},{"count":96,"reaction":"INTRAOCULAR PRESSURE INCREASED"},{"count":91,"reaction":"ENDOPHTHALMITIS"},{"count":91,"reaction":"UVEITIS"},{"count":82,"reaction":"CONDITION AGGRAVATED"},{"count":76,"reaction":"DRUG INEFFECTIVE"},{"count":67,"reaction":"OFF LABEL USE"},{"count":65,"reaction":"NAUSEA"},{"count":62,"reaction":"CHOROIDITIS"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"chemblId":"CHEMBL1201302"},"formularyStatus":[],"_approvalHistory":[{"date":"19960318","type":"SUPPL","sponsor":"HARROW EYE","applicationNumber":"NDA013422"},{"date":"19830805","type":"SUPPL","sponsor":"HARROW EYE","applicationNumber":"NDA013422"},{"date":"19951101","type":"SUPPL","sponsor":"HARROW EYE","applicationNumber":"NDA013422"},{"date":"19810805","type":"SUPPL","sponsor":"HARROW EYE","applicationNumber":"NDA013422"},{"date":"19790706","type":"SUPPL","sponsor":"HARROW EYE","applicationNumber":"NDA013422"},{"date":"20210514","type":"SUPPL","sponsor":"HARROW EYE","applicationNumber":"NDA013422"},{"date":"19900531","type":"SUPPL","sponsor":"HARROW EYE","applicationNumber":"NDA013422"},{"date":"19990311","type":"SUPPL","sponsor":"HARROW EYE","applicationNumber":"NDA013422"},{"date":"20160310","type":"SUPPL","sponsor":"HARROW EYE","applicationNumber":"NDA013422"},{"date":"20021211","type":"SUPPL","sponsor":"HARROW EYE","applicationNumber":"NDA013422"},{"date":"20130927","type":"SUPPL","sponsor":"HARROW EYE","applicationNumber":"NDA013422"},{"date":"19891206","type":"SUPPL","sponsor":"HARROW EYE","applicationNumber":"NDA013422"},{"date":"20000204","type":"SUPPL","sponsor":"HARROW EYE","applicationNumber":"NDA013422"},{"date":"19620620","type":"ORIG","sponsor":"HARROW EYE","applicationNumber":"NDA013422"},{"date":"19960926","type":"SUPPL","sponsor":"HARROW EYE","applicationNumber":"NDA013422"},{"date":"19840321","type":"SUPPL","sponsor":"HARROW EYE","applicationNumber":"NDA013422"},{"date":"19990407","type":"SUPPL","sponsor":"HARROW EYE","applicationNumber":"NDA013422"},{"date":"19951101","type":"SUPPL","sponsor":"HARROW EYE","applicationNumber":"NDA013422"},{"date":"19840808","type":"SUPPL","sponsor":"HARROW EYE","applicationNumber":"NDA013422"},{"date":"19950614","type":"SUPPL","sponsor":"HARROW EYE","applicationNumber":"NDA013422"},{"date":"19790706","type":"SUPPL","sponsor":"HARROW EYE","applicationNumber":"NDA013422"},{"date":"20211210","type":"SUPPL","sponsor":"HARROW EYE","applicationNumber":"NDA013422"},{"date":"20171103","type":"SUPPL","sponsor":"HARROW EYE","applicationNumber":"NDA013422"},{"date":"19990205","type":"SUPPL","sponsor":"HARROW EYE","applicationNumber":"NDA013422"},{"date":"20160805","type":"SUPPL","sponsor":"HARROW EYE","applicationNumber":"NDA013422"},{"date":"20030417","type":"SUPPL","sponsor":"HARROW EYE","applicationNumber":"NDA013422"},{"date":"19980804","type":"SUPPL","sponsor":"HARROW EYE","applicationNumber":"NDA013422"},{"date":"20150407","type":"SUPPL","sponsor":"HARROW EYE","applicationNumber":"NDA013422"},{"date":"19891128","type":"SUPPL","sponsor":"HARROW EYE","applicationNumber":"NDA013422"},{"date":"20021204","type":"SUPPL","sponsor":"HARROW EYE","applicationNumber":"NDA013422"},{"date":"19961017","type":"SUPPL","sponsor":"HARROW EYE","applicationNumber":"NDA013422"},{"date":"19880302","type":"SUPPL","sponsor":"HARROW EYE","applicationNumber":"NDA013422"},{"date":"19990817","type":"SUPPL","sponsor":"HARROW EYE","applicationNumber":"NDA013422"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":34,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Maxidex","genericName":"Maxidex","companyName":"Alcon Research","companyId":"alcon-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:56:42.708743+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}